Biomarkers and Adjuvant Treatment Planning Strategies for Patients with a Node-Negative, Estrogen Receptor-Positive Breast Cancer
David M. Hyams, MD, FACS and Ruth Oratz, MD, FACP

Molecularly Targeted Therapies for Breast Cancer
Timothy J. Hobday, MD; Edith A. Perez, MD

Monoclonal Antibody Therapy for Breast Cancer
Edith A. Perez, MD - Mayo Clinic Cancer Center, Jacksonville, Florida

Medical Genomics: Implications for Clinical Oncology
Charles H. Weaver, MD, and Dayna Deuter

Radiofrequency Ablation Effective for Lung Tumors (7/22/2008)
Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.

New Taxoid, Larotaxel, Effective for Breast Cancer Patients Previously Treated with Taxanes (6/30/2008)
Researchers involved in an international Phase II study have reported that larotaxel (XRP9881) has significant activity in taxane-resistant metastatic breast cancer. The details of this study were published in the July 7, 2008 issue of the Annals of Oncology.

Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates (6/25/2008)
Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.

Oncotype DX® Assay Compares Favorably with Immunohistochemistry for ER and PR Status of Breast Cancer (6/13/2008)
Researchers affiliated with Eastern Cooperative Group (ECOG) study E2197 have reported that the reverse-transcriptase polymerase chain reaction (RT-PCR) assay, Oncotype DX®, has a high concordance with immunohistochemistry (IHC) for determination of estrogen receptor (ER) and progesterone receptor (PR) status of localized breast cancer. The details of this study were published in the May 20, 2008 issue of the Journal of Clinical Oncology.

Addition of Avastin® to Taxotere® Improves Progression-free Survival in Advanced HER2-negative Breast Cancer (6/6/2008)
Researchers from Europe reported results from the AVEDO trial, which indicated that the addition of Avastin® (bevacizumab) to Taxotere® (docetaxel) improves progression-free survival compared with Taxotere alone in metastatic HER2-negative breast cancer. Furthermore, higher doses of Avastin resulted in improved progression-free survival. These results were recently reported as a late-breaking abstract at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).